

REC Ref No.	IRAS No.	Name of Trial	Target Number of Participants Available?	Recruitment Target	Target Date To Recruit Participants Available?	Date Agreed To Recruit Target Number of Participants	Total Number of Participants Recruited at The Agreed Target Date	Date Study Closed to Recruitment	Recruitment Total	RTT Met?	Recruitment Closure Reason
20/NW/0383	287807	A Phase 3 Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734TM) Treatment of COVID-19 in an Outpatient Setting	Number Agreed	12	Date Agreed	30/06/2021	0	30/06/2021	0	No	Withdrawn by Sponsor
20/SC/0111	276734	A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants with Relapsed/Refractory Multiple Myeloma	Number Agreed	2	Date Agreed	31/05/2021	2	01/07/2021	2	Yes	Recruitment Finished
20/LO/1278	288502	A multicenter, Phase 2a, open-label, non-randomized study evaluating the efficacy, safety, and tolerability of BIVV020 in adults with persistent/chronic immune thrombocytopenia (ITP)-PDY16894	Number Agreed	1	Date Agreed	31/07/2021	0	31/07/2021	0	No	Withdrawn by Sponsor
20/EE/0170	1003070	Multicenter, randomized, placebo controlled, double-blind, parallel group, dose-finding Phase 2 study to evaluate the efficacy and safety of BAY 2433334 in patients following an acute myocardial infarction	Number Agreed	5	Date Agreed	14/07/2021	5	14/07/2021	5	Yes	Recruitment Finished
20/EE/0204	287569	A PHASE II, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY TO EVALUATE THE PHARMACODYNAMIC EFFECTS OF ONCE WEEKLY ADMINISTRATION OF GANTENERUMAB IN PARTICIPANTS WITH EARLY (PRODRIMAL TO MILD) ALZHEIMER–S DISEASE	Number Agreed	6	Date Agreed	01/07/2021	11	01/07/2021	11	Yes	Recruitment Finished
20/YH/0171	284062	An open-label, adaptive randomized, controlled multicenter study to evaluate the efficacy and safety of RESP301 plus standard of care (SOC) compared to SOC alone in hospitalized participants with COVID-19 WHO grade 3&4 (NOCov2)	Number Agreed	10	Date Agreed	31/07/2021	14	31/07/2021	14	Yes	Recruitment Finished
20/EM/0087	274214	An open-label, randomised, multicentre, phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracil/leucovorin versus nab-paclitaxel plus gemcitabine in subjects who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas.	Number Agreed	2	Date Agreed	31/07/2021	2	27/07/2021	2	Yes	Recruitment Finished
19/EE/0379	269900	IPX203-B16-03	Number Agreed	1	Date Agreed	31/12/2021	0	31/03/2021	0	No	Recruitment Finished
18/EM/0323	251531	A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft-Versus-Host Disease in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation	Number Agreed	2	Date Agreed	23/04/2021	0	16/04/2021	0	No	Withdrawn by Sponsor
20/EE/0031	275993	Multicenter, randomized, placebo-controlled, double-blind, parallel group, dose-finding Phase 2 study to evaluate efficacy and safety of BAY 2433334 in patients following an acute noncardioembolic ischemic stroke	Number Agreed	10	Date Agreed	31/08/2021	10	31/08/2021	10	Yes	Recruitment Finished

18/WS/0218	252602	An open-label, multicentre study to evaluate pharmacokinetics, safety and efficacy of zamicastat as adjunctive therapy in pulmonary arterial hypertension (PAH)	Number Agreed	1	Date Agreed	30/06/2021	0	30/06/2021	0	No	Recruitment Finished
19/NW/0336	256297	Radiographic imaging Validation and EvALuation for Angio iFR (ReVEAL iFR)	Number Agreed	20	Date Agreed	01/08/2021	9	01/08/2021	9	No	Recruitment Finished
19/LO/1583	271866	A Phase 2, Open Label, Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Voxelotor in Patients with Sickle Cell Disease	Number Agreed	5	Date Agreed	03/06/2021	2	12/02/2021	2	No	Withdrawn by Sponsor
19/NE/0312	266862	AN OPEN LABEL PHASE 1A/B STUDY OF MTL-CEBPA IN COMBINATION WITH A PD-1 INHIBITOR (PEMBROLIZUMAB) IN ADULT PATIENTS WITH ADVANCED SOLID TUMOURS (TIMEPOINT)	Number Agreed	5	Date Agreed	31/08/2021	6	31/08/2021	6	Yes	Recruitment Finished
19/LO/1756	272037	A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma/ CA209-9DW	Number Agreed	2	Date Agreed	01/09/2021	0	01/09/2021	0	No	Recruitment Finished
17/SC/0605	234167	A phase 1/2 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of CTX-SPL9111 (a cabazitaxel (CTX)-dendrimer conjugate) in patients with advanced solid tumours	Number Agreed	3	Date Agreed	31/08/2021	9	31/08/2021	9	Yes	Recruitment Finished
19/SC/0422	268966	An Open-Label, Long-Term Safety Evaluation Study with DCCR	Number Agreed	3	Date Agreed	15/03/2021	1	15/03/2021	1	No	Recruitment Finished
19/LO/1263	263485	A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk	Number Agreed	1	Date Agreed	01/12/2020	1	01/12/2020	1	Yes	Recruitment Finished
19/NW/0328	263312	A Phase 2 Randomized, Double-Blind, Placebo Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Ulcerative Colitis	Number Agreed	2	Date Agreed	31/12/2020	0	15/03/2021	0	No	Recruitment Finished
18/NE/0360	254062	An open-label, non-randomised study on efficacy, pharmacokinetics, pharmacodynamics, safety and tolerability of LNP023 in two patient populations with C3 glomerulopathy	Number Agreed	2	Date Agreed	31/03/2021	3	31/03/2021	3	Yes	Recruitment Finished
19/NW/0174	261666	A Phase III Randomized, Double-Blind, Placebo-Controlled, Multi-Regional, International Study of Durvalumab in Combination with Gemcitabine plus Cisplatin versus Placebo in Combination with Gemcitabine plus Cisplatin for Patients with First-Line Advanced Biliary Tract Cancers	Number Agreed	3	Date Agreed	31/12/2020	6	30/10/2020	6	Yes	Recruitment Finished
19/WS/0015	257933	A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of T-817MA in Patients with Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease	Number Agreed	6	Date Agreed	25/06/2021	0	31/03/2021	1	No	Recruitment Finished
19/NE/0247	259906	A Phase 2, Double-blind, Active-controlled, Dose-titrating Efficacy and Safety Study of Firibastat (QGC001) Compared to Ramipril Administered Orally, Twice Daily, Over 12 Weeks to Prevent Left Ventricular Dysfunction after Acute Myocardial Infarction	Number Agreed	1	Date Agreed	30/06/2021	1	15/04/2021	1	Yes	Recruitment Finished

19/EE/0168	262098	A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1, and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression (LEAP-011)	Number Agreed	2	Date Agreed	30/09/2021	0	30/09/2021	0	No	Recruitment Finished
19/EM/0020	252705	A phase II, open-label, prospective, single-arm, study to assess ability of eltrombopag to induce sustained remission in subjects with ITP who are refractory or relapsed after first-line steroids (TAPER)	Number Agreed	2	Date Agreed	30/11/2020	3	30/11/2020	3	Yes	Recruitment Finished
19/NW/0342	264974	A Phase 3/4, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)	Number Agreed	2	Date Agreed	20/12/2020	0	20/12/2020	0	No	Recruitment Finished
18/SC/0591	250421	A Randomized, Open Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor of High Tumor Mutational Burden (TMB-H)	Number Agreed	3	Date Agreed	21/01/2021	3	15/01/2021	3	Yes	Recruitment Finished
18/LO/1258	248312	Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis	Number Agreed	2	Date Agreed	30/09/2019	1	31/12/2020	1	No	Withdrawn by Sponsor
19/SC/0350	266934	A Phase 1B, Randomized, Subject- and Investigator-Blinded, Placebo-Controlled, Multi-Center Clinical Trial to Evaluate the Safety and Pharmacokinetics of Inhaled GB002, and Assess Changes in Imaging and Biomarkers in Subjects with WHO Group 1 Pulmonary Arterial Hypertension (PAH)	Number Agreed	2	Date Agreed	31/12/2020	1	31/12/2020	1	Yes	Recruitment Finished
18/EM/0311	254008	A Phase 2, Single-Center, Double-Blind, Placebo-Controlled, Study of PUL-042 Inhalation Solution in Rhinovirus-induced Symptoms in Current Smokers with Gold Stage 0 Chronic Obstructive Pulmonary Disease (COPD)	Number Agreed	20	Date Agreed	01/08/2019	18	21/06/2021	19	No	Recruitment Finished
17/LO/0232	220795	An Open-Label, Randomized, Crossover Trial utilizing a Single-Blinded Rater to evaluate APL-130277 compared to s.c. Apomorphine in Levodopa Responsive Subjects with Parkinson's Disease Complicated by Motor Fluctuations	Number Agreed	4	Date Agreed	17/03/2021	1	17/03/2021	2	No	Withdrawn by Sponsor
18/SC/0240	230920	A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of Gantenerumab in Patients with Early (Prodromal to Mild) Alzheimer's Disease	Number Agreed	8	Date Agreed	11/01/2021	9	11/01/2021	9	Yes	Recruitment Finished
18/NW/0765	250220	Validating a Device for the Detection of Bacteria and Leukocytes in Peritoneal Effluent from Patients with Suspected Peritonitis	Number Agreed	10	Date Agreed	02/11/2020	13	31/12/2020	13	Yes	Recruitment Finished
18/LO/1215	245798	A Randomized, Phase 3 Study of Eryaspase in Combination with Chemotherapy versus Chemotherapy Alone as Second-Line Treatment in Patients with Pancreatic Adenocarcinoma TRYbeCA-1 â€” TRial of erYaspase in pancreatic CAncer	Number Agreed	2	Date Agreed	30/08/2020	2	01/12/2020	2	Yes	Recruitment Finished

18/LO/1882	253030	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer	Number Agreed	2	Date Agreed	16/11/2020	2	23/10/2020	2	Yes	Recruitment Finished
18/NW/0514	249725	SELECT - Semaglutide effects on cardiovascular outcomes in people with overweight or obesity	Number Agreed	34	Date Agreed	23/10/2020	34	23/10/2020	34	Yes	Recruitment Finished
18/NE/0142	242919	A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis	Number Agreed	2	Date Agreed	06/05/2021	2	06/05/2021	2	Yes	Recruitment Finished
18/NE/0136	240494	A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation	Number Agreed	1	Date Agreed	01/05/2020	0	18/12/2020	0	No	Recruitment Finished
17/LO/1500	224823	A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation Who are candidates for Non-intensive Therapy.	Number Agreed	1	Date Agreed	19/09/2022	0	26/05/2021	0	No	Withdrawn by Sponsor
17/WS/0180	225790	A Phase 111b, Randomised, Double-blind, Placebocontrolled, MulticentreStudy of Olaparib Maintenance Retreatment in Patients with EpithelialOvarian Cancer Previously Treated With a PARPi and Responding toRepeat Platinum Chemotherapy (OReO)	Number Agreed	4	Date Agreed	30/04/2021	1	15/01/2021	2	No	Recruitment Finished
17/LO/1590	229278	A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) plus Chemotherapy (XP or FP) versus Placebo plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects with Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585).	Number Agreed	4	Date Agreed	01/03/2021	4	31/12/2020	5	Yes	Recruitment Finished
16/EE/0421	209972	A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients with Open-Angle Glaucoma or Ocular Hypertension	Number Agreed	2	Date Agreed	31/05/2021	0	31/05/2021	0	No	Recruitment Finished
16/SS/0115	206867	MK-8931-019: Long Term Safety and Efficacy Trial of MK-8931	Number Agreed	5	Date Agreed	01/09/2021	1	01/09/2021	1	No	Recruitment Finished